BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 2416957)

  • 1. Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can be located outside or inside the antibody-binding site.
    Blondel B; Crainic R; Fichot O; Dufraisse G; Candrea A; Diamond D; Girard M; Horaud F
    J Virol; 1986 Jan; 57(1):81-90. PubMed ID: 2416957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poliovirus Sabin type 1 neutralization epitopes recognized by immunoglobulin A monoclonal antibodies.
    Fiore L; Ridolfi B; Genovese D; Buttinelli G; Lucioli S; Lahm A; Ruggeri FM
    J Virol; 1997 Sep; 71(9):6905-12. PubMed ID: 9261417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mapping of type 1 poliovirus neutralization epitopes.
    Blondel B; Crainic R; Dufraisse G; Candréa A; Horaud F
    Dev Biol Stand; 1985; 60():337-42. PubMed ID: 2412917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigenic structure of polioviruses of serotypes 1, 2 and 3.
    Minor PD; Ferguson M; Evans DM; Almond JW; Icenogle JP
    J Gen Virol; 1986 Jul; 67 ( Pt 7)():1283-91. PubMed ID: 2425046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Principal and subsidiary antigenic sites of VP1 involved in the neutralization of poliovirus type 3.
    Minor PD; Evans DM; Ferguson M; Schild GC; Westrop G; Almond JW
    J Gen Virol; 1985 May; 66 ( Pt 5)():1159-65. PubMed ID: 2582084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of monoclonal antibodies for the identification of the antigenic site for poliovirus neutralization.
    Minor PD; Schild GC; Evans D; Ferguson M; Almond J
    Dev Biol Stand; 1984; 57():171-5. PubMed ID: 6084608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different virus-precipitating activities of neutralizing monoclonal antibodies that recognize distinct sites of poliovirus particles.
    Taniguchi K; Urasawa S
    Arch Virol; 1987; 92(1-2):27-40. PubMed ID: 2432854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of a monoclonal antibody and of DNA recombinant technology for the localization of a poliovirus neutralization epitope in viral capsid polypeptide VP1.
    Bruneau P; van der Werf S; Wychowski C; Siffert O; Girard M
    Dev Biol Stand; 1984; 57():177-85. PubMed ID: 6084609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for a complex structure of neutralization antigenic site I of poliovirus type 1 Mahoney.
    Wiegers K; Uhlig H; Dernick R
    J Virol; 1988 May; 62(5):1845-8. PubMed ID: 2451760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigenic sites of poliovirus type 3 eliciting IgA monoclonal antibodies in orally immunized mice.
    Buttinelli G; Ruggeri FM; Marturano J; Novello F; Donati V; Fiore L
    Virology; 2001 Mar; 281(2):265-71. PubMed ID: 11277698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poliovirus neutralization epitopes: analysis and localization with neutralizing monoclonal antibodies.
    Emini EA; Jameson BA; Lewis AJ; Larsen GR; Wimmer E
    J Virol; 1982 Sep; 43(3):997-1005. PubMed ID: 6183443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-AgIB of poliovirus type 1: a discontinuous epitope formed by two loops of VP1 comprising residues 96-104 and 141-152.
    Wiegers K; Uhlig H; Dernick R
    Virology; 1989 Jun; 170(2):583-6. PubMed ID: 2471354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection by monoclonal antibodies of an antigenic determinant critical for poliovirus neutralization present on VP1 and on heat-inactivated virions.
    Blondel B; Akacem O; Crainic R; Couillin P; Horodniceanu F
    Virology; 1983 Apr; 126(2):707-10. PubMed ID: 6190311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigenic analysis of poliovirus type 3 using monoclonal antibodies.
    Ferguson M; Minor PD; Magrath DI; Schild GC
    Dev Biol Stand; 1984; 57():151-5. PubMed ID: 6098495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigenic modification of attenuated Sabin type 1 poliovirus by in vitro passages at supraoptimal temperatures.
    Crainic R; Blondel B; Candréa A; Dufraisse G; Horaud F
    Dev Biol Stand; 1985; 60():343-7. PubMed ID: 2995173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibodies reactive with different sites of N and H antigenic particles of poliovirus.
    Taniguchi K; Urasawa S; Urasawa T
    J Gen Virol; 1983 Dec; 64 ( Pt 12)():2803-8. PubMed ID: 6198442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determining the epitope dominance on the capsid of a serotype SAT2 foot-and-mouth disease virus by mutational analyses.
    Opperman PA; Rotherham LS; Esterhuysen J; Charleston B; Juleff N; Capozzo AV; Theron J; Maree FF
    J Virol; 2014 Aug; 88(15):8307-18. PubMed ID: 24829347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigenic variation of poliovirus studied by means of monoclonal antibodies.
    Crainic R; Blondel B; Horaud F
    Rev Infect Dis; 1984; 6 Suppl 2():S535-9. PubMed ID: 6204369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies of the antigenic variation in poliovirus type 1. Selection and analysis of variant strains with monoclonal antibodies by neutralization.
    Thibodeau L; Lacroix M; Lecomte J; Fauvel M
    Dev Biol Stand; 1984; 57():157-63. PubMed ID: 6084606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Critical role of an eight-amino acid sequence of VP1 in neutralization of poliovirus type 3.
    Evans DM; Minor PD; Schild GS; Almond JW
    Nature; 1983 Aug 4-10; 304(5925):459-62. PubMed ID: 6192344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.